肌肉骨骼医学中的肽疗法 资料

本页面由机器翻译,尚未经临床医生审核。英文版本为权威版本。

什么是肽疗法

肽是您身体本来就在使用的微小信号分子,用来告诉细胞该做什么。在骨科领域,人们正在研究将肽用于治疗受伤的肌腱、韧带、软骨和骨骼。有些肽,例如骨形态发生蛋白,是体内天然存在的。另一些则是在实验室中设计出来的,用于模仿或增强这些天然信号 [1]。

目前,用于运动和肌肉骨骼问题的注射用肽在很大程度上仍处于试验阶段 [2]。目前还没有足够可靠的证据支持在日常治疗中使用它们 [3]。由于安全性和有效性数据很少,现阶段肽类补充剂既不应代替、也不应叠加在标准骨科治疗之上 [4]。如果您在网上看到过宣传肽可治疗肌腱或关节问题,需要了解的是,研究还没有跟上营销的步伐。

少数肽类相关治疗的依据较为可靠。两种促进骨愈合的蛋白 BMP-2 和 BMP-7 有高质量研究支持 [5],并已获得监管部门批准用于特定的骨折问题 [6]。生长因子是与之相关的信号分子,也显示出前景。其中一种称为血小板衍生生长因子,如果在受伤后不久使用,可能有助于韧带愈合 [7]。另一种称为胰岛素样生长因子-I,可能对严重受损的肌腱有帮助 [8]。这些与面向一般用途销售的肽类补充剂并不相同,而且是在严格的医疗监督下使用的。

它们是如何起作用的?可以把肽想象成开启修复过程的信使。它们可以促使细胞生成更多胶原蛋白,胶原蛋白是赋予肌腱强度的纤维 [9]。它们还可以减轻关节炎症,并帮助软骨细胞恢复更正常的活动 [10]。研究人员仍在研究哪些信号对哪种组织有帮助,以及如何安全地给药 [11]。

它有效吗?

坦白地说,对于大多数注射用肽,我们目前还不知道。BPC-157 根本没有任何人体随机对照试验,因此无法判断它是否有效、是否安全,或者可能对谁有帮助 [12]。骨科和运动医学专科医生被建议在提供这些注射之前先了解这一证据空白 [3]。

一些肽类相关治疗在早期研究中确实显示出前景,但大部分研究是在动物或实验室中完成的,而不是在像您这样的人身上。在大鼠研究中,某些生长因子帮助肌腱和韧带愈合得更牢固 [7] [13],一种名为 sprifermin 的生长因子促进了微骨折手术后的软骨修复 [14]。一种与神经相关的生长因子帮助大鼠骨折更快愈合 [15]。这些发现只是起点,而不是证据。

有些结果好坏参半或令人失望。在兔子的肢体延长过程中,不建议使用一种名为 VEGF 的生长因子来帮助骨形成 [16]。单独使用一种支架有助于稳定较大的骨缺损,但并未实现完全的骨愈合,也未能恢复正常强度 [17]。GLP-1 激动剂是一种治疗糖尿病和减重的药物,有时会在关节置换手术的背景下被提及,但它可能无法带来足够的体重减轻,使体重指数达到该手术通常要求的水平 [18]。

还需要了解的是,社交媒体上关于肽的大多数帖子依据的是实验室或动物数据,或个人经历,并把肽宣传为几乎能解决任何问题的方法 [19]。这与来自严谨人体试验的证据并不相同。

因此,如果您正在考虑肽疗法,公平的总结是:少数相关治疗显示出早期前景,但如今直接面向您营销的注射剂缺乏证明其有效或安全所需的试验。您的医生可以向您说明哪些已经过适当检验,哪些还没有。

风险有哪些?

坦白地说,目前还没有人完全了解其风险。对于大多数注射用肽,没有可靠的人体试验追踪会出现哪些问题,因此您可能出现的副作用从未被正确统计过 [3]。这一空白本身就是一种风险,这也是为什么现阶段肽类补充剂既不应代替、也不应叠加在您的标准骨科治疗之上 [4]。

研究中已经发现了一些风险。组织对生长因子的反应可能因治疗的身体部位不同而不同,因此对一条肌腱有帮助的剂量在另一条肌腱上可能表现不同 [11]。在关节研究中,抑制一种与神经相关的生长因子所产生的效果,会因关节炎的严重程度不同而不同 [20]。在骨愈合方面,不建议在肢体延长过程中使用一种名为 VEGF 的生长因子来帮助骨形成 [16]。

您可能购买的产品本身也存在风险。社交媒体上关于肽的大多数帖子依据的是实验室或动物数据,或个人经历,并把肽宣传为几乎能解决任何问题的方法 [19]。没有人体试验,就无法判断某个产品是否有效、是否安全,或是否适合您的病情 [12]。

少数相关治疗有更可靠的安全性数据。两种促进骨愈合的蛋白 BMP-2 和 BMP-7 有高质量研究支持 [5]。在实验室中用生长因子处理软骨细胞,从端粒生物学的角度来看被认为是安全的 [21]。但这些治疗是在严格的医疗监督下使用的,而不是作为补充剂出售。

如果您正在考虑肽疗法,请询问该特定产品有哪些人体证据、记录到了哪些副作用,以及您的医生将如何监测您。如果这些问题的答案很单薄,这本身就告诉了您一些重要的信息。

这适合您吗?

对于大多数阅读本页的人来说,坦白的答案可能是:暂时还不适合。针对肌腱、关节和骨骼问题营销的注射用肽类补充剂尚未在人体中得到充分检验,无法知道谁能从中获益 [3]。由于安全性和有效性数据很少,现阶段它们既不应代替、也不应叠加在您的标准骨科治疗之上 [4]。

一小部分相关治疗属于不同的类别。在受伤后不久使用的生长因子可能有助于某些肌腱和韧带愈合 [7] [8],两种促进骨愈合的蛋白已获得监管部门批准用于特定的骨折问题 [6]。如果您的病情符合其中之一,您的医生可能会将其作为有监督的治疗计划的一部分与您讨论。这是一项医疗决定,而不是购买补充剂。

谁可能不会获益?如果您在网上看到肽被宣传为从运动表现到外貌几乎能解决任何问题的方法,这种营销依据的是实验室研究和个人经历,而不是人体试验 [19]。没有任何试验表明这些产品对日常的关节和肌肉不适有效。

与主要的替代方案相比,物理治疗、标准注射和手术等成熟治疗方法背后的证据要强得多。对于大多数肌肉骨骼问题,肽疗法仍处于试验阶段 [2]。

这应当是您与医生共同做出的决定。请询问该特定产品有哪些人体证据,并在做决定之前阅读上面的风险部分。如果答案很单薄,目前标准治疗是更安全的选择。

核心要点

对于大多数针对肌腱、关节和骨骼问题销售的肽注射剂,坦白的答案是:暂时还不行。它们背后没有可靠的人体试验,因此不应代替或叠加在您的标准骨科治疗之上 [3] [4]。少数相关治疗,例如用于肌腱的生长因子和已获批准的促进骨愈合的蛋白,在医疗监督下显示出前景 [7] [8] [6]。如果您感兴趣,请谨慎对待网上的宣传,因为大多数营销依据的是实验室和动物研究,而不是人体试验 [19]。最重要的一点提醒:在考虑任何特定产品之前,请先询问它有哪些人体证据。

参考文献

[1] Peptide Therapeutics in Orthopaedics. Journal of Bone and Joint Surgery. 2026. DOI: 10.2106/jbjs.26.00785

[2] Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS Reviews. 2026. DOI: 10.2106/jbjs.rvw.26.00027

[3] Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American Journal of Sports Medicine. 2026. DOI: 10.1177/03635465251357593

[4] Peptide Supplements and Their Therapeutic Applications in Sports Medicine. The American Journal of Sports Medicine. 2026. DOI: 10.1177/03635465261464420

[5] Carrier systems and application of growth factors in orthopaedics. Injury. 2008. DOI: 10.1016/s0020-1383(08)70014-7

[6] Clinical applications of growth factors in bone injuries: Experience with BMPs. Injury. 2013. DOI: 10.1016/s0020-1383(13)70008-1

[7] Influence of dosage and timing of application of platelet‐derived growth factor on early healing of the rat medial collateral ligament. Journal of Orthopaedic Research. 1996. DOI: 10.1002/jor.1100140509

[8] Insulin‐like growth factor‐I improves cellular and molecular aspects of healing in a collagenase‐induced model of flexor tendinitis. Journal of Orthopaedic Research. 2002. DOI: 10.1016/s0736-0266(02)00009-8

[9] The pentapeptide KTTKS promoting the expressions of type I collagen and transforming growth factor‐β of tendon cells. Journal of Orthopaedic Research. 2007. DOI: 10.1002/jor.20455

[10] Dual transduction of insulin‐like growth factor‐I and interleukin‐l receptor antagonist protein controls cartilage degradation in an osteoarthritic culture model. Journal of Orthopaedic Research. 2005. DOI: 10.1016/j.orthres.2004.06.020

[11] Patellar tendon and anterior cruciate ligament have different mitogenic responses to platelet‐derived growth factor and transforming growth factor β. Journal of Orthopaedic Research. 1996. DOI: 10.1002/jor.1100140407

[12] Injectable Therapeutic Peptides—An Adjunct to Regenerative Medicine and Sports Performance?. Arthroscopy. 2024. DOI: 10.1016/j.arthro.2024.09.005

[13] Comparison of the effect of intra‐tendon applications of recombinant human platelet‐derived growth factor‐BB, platelet‐rich plasma, steroids in a rat achilles tendon collagenase model. Journal of Orthopaedic Research. 2013. DOI: 10.1002/jor.22483

[14] Recombinant fibroblast growth factor‐18 (sprifermin) enhances microfracture‐induced cartilage healing. Journal of Orthopaedic Research. 2021. DOI: 10.1002/jor.25063

[15] Topical application of nerve growth factor improves fracture healing in rats. Journal of Orthopaedic Research. 1997. DOI: 10.1002/jor.1100150212

[16] Effects of locally applied vascular endothelial growth factor (VEGF) and VEGF‐inhibitor to the rabbit tibia during distraction osteogenesis. Journal of Orthopaedic Research. 2003. DOI: 10.1016/s0736-0266(02)00159-6

[17] Quantitative assessment of scaffold and growth factor‐mediated repair of critically sized bone defects. Journal of Orthopaedic Research. 2007. DOI: 10.1002/jor.20372

[18] Glucagon-like Peptide-1 Agonists. JBJS Reviews. 2024. DOI: 10.2106/jbjs.rvw.23.00167

[19] Paper 32. Performance & Promises: A Social Media Review of Alleged Indications, Risks and Usage of “Peptides” in Musculoskeletal Health. Orthopaedic Journal of Sports Medicine. 2026. DOI: 10.1177/2325967126s00290

[20] Nerve growth factor receptors in equine synovial membranes vary with osteoarthritic disease severity. Journal of Orthopaedic Research. 2022. DOI: 10.1002/jor.25382

[21] Influence of the growth factors PDGF‐BB, TGF‐β1 and bFGF on the replicative aging of human articular chondrocytes during in vitro expansion. Journal of Orthopaedic Research. 2009. DOI: 10.1002/jor.21007


Evidence & references

This is the clinical evidence summary written for health professionals. It is technical, and it lists the research this page was built from. You do not need to read it to understand your treatment or to make a decision about it.

Overview

  • Peptide therapeutics in orthopaedics have evolved from naturally occurring agents like bone morphogenetic proteins to rationally engineered synthetics [3].
  • Injectable peptides for sports medicine remain largely experimental [8].
  • While peptide therapy may possess significant therapeutic and regenerative potential, there is a current lack of evidence to support the clinical use of these peptides [1].
  • Because of the lack of robust efficacy and safety data, peptide supplements should not currently be recommended as a replacement or adjunct for existing orthopaedic standard of care [4].
  • Growth factors play a critical role in the biologic processes that drive tendons to heal [5].
  • Platelet-derived growth factor has promise for healing ligaments but must be administered in appropriate doses soon after injury [7].
  • Data support the potential use of intralesional IGF-I for treatment of debilitating tendon injuries [9].
  • Only BMP-2 and BMP-7 can be recommended based on level I studies [10].
  • A myofibroblast–mast cell–neuropeptide axis of fibrosis in the joint capsules in post-traumatic contractures has been identified as a potential target for prophylactic or therapeutic interventions [11].
  • Parathyroid hormone-related peptide may be involved in the pathophysiology of osteoarthritis [12].
  • Osteogenic growth peptide treatment resulted in a stronger expression of transforming growth factor-β, both locally and systemically, in rat fracture healing specimens [13].
  • Local delivery of specific neuropeptides could reverse the functional deficits of neuropathic ligaments in only 2 weeks in a rat model [15].
  • The effect of transforming growth factor-β1 on the expression of the type-II collagen gene was observed as early as 12 hours after administration, but this effect was not observed in response to bone morphogenetic proteins 3 or 4 [20].
  • VEGF is not recommended for enhancement of bone formation during distraction osteogenesis [22].
  • In the first 2 weeks after lesion induction, tissue levels of IGF-I protein decreased approximately 40% compared to normal tendon [31].
  • The use of BMP currently has two FDA-approved indications: treatment of open tibial fractures treated with intramedullary fixation and treatment of tibia long bone non-union [57].
  • Chondrocyte-binding peptides may be coupled to therapeutic molecules to provide targeted treatment for cartilage disorders [2].
  • The term “medicinal signaling cells” has important implications for orthopaedic surgeons when counseling patients, selecting biologic adjuncts, interpreting outcome data, and designing future clinical trials [21].
  • Loss of function in musculoskeletal tissues initiates from either a failure of the cells that produce and maintain the extracellular matrix or as a consequence of material failure of the extracellular matrix itself [43].
  • Advances in the identification of candidate therapeutic cell populations and the development of new biomaterials have occurred over the last three decades to address degenerative processes in musculoskeletal tissues [43].

How It Works

Current Clinical Status and Safety

  • There is a current lack of evidence to support the clinical use of injectable peptides [1].
  • Peptide supplements should not currently be recommended as a replacement or adjunct for existing orthopaedic standard of care due to the lack of robust efficacy and safety data [4].
  • Regenerative medicine holds great promise for orthopaedic surgery by developing novel therapies that replace, repair, or promote tissue regeneration [19].

Bone Healing and Fracture Repair

  • Osteogenic growth peptide treatment results in a stronger expression of transforming growth factor-β both locally and systemically in rat fracture models [13].
  • Topical application of nerve growth factor increases the effectiveness and rate of repair of bone in rat fracture models [18].
  • Local growth factor application enhances healing in the early phase without alteration of the normal healing process [35].
  • Mesenchymal stem cell expression of stromal cell-derived factor-1β provides potent synergistic effects supporting bone formation in local regenerative therapy models [41].

Tendon and Ligament Healing

  • Insulin-like growth factor-I improves cellular and molecular aspects of healing in a collagenase-induced model of flexor tendinitis [9].
  • Recombinant human platelet-derived growth factor-BB treatment is an effective therapy and may be an option for clinical applications to treat tendinopathy [16].
  • Tissue responses to growth factors in tendons and ligaments may vary at different anatomic sites [17].
  • The pentapeptide KTTKS promotes the expressions of type I collagen and transforming growth factor-β of tendon cells [23].
  • Interventions developed to improve healing of flexor tendons must address differences in regulation between tendon and tendon sheath because they will likely affect the outcomes [40].
  • The IGFBP response of flexor tendons to injury and healing provides information necessary for the design of protocols that may enhance tendon healing through manipulation of IGF-I ligand and binding protein levels [42].

Cartilage and Osteoarthritis

  • Chondrocyte-binding peptides identified by phage display may be coupled to therapeutic molecules to provide targeted treatment for cartilage disorders [2].
  • Effective mechanisms of growth factor delivery for articular cartilage repair may differ for different growth factors [24].
  • Transduction with interleukin-1 receptor antagonist protein decreased the synovial expression of interleukin-1α, interleukin-1β, and matrix metalloproteinases, indicating a mechanism for prevention of matrix degradation [25].
  • Cartilage fragments from osteoarthritic knees promote chondrogenic differentiation of mesenchymal stem cells without exogenous growth factor induction [37].
  • The actions of insulin-like growth factor binding proteins 2 and 3 in articular cartilage extend beyond the classic modulation of IGF receptor action [38].
  • Transforming growth factor-β exerts at least some of its actions in articular cartilage via cross-talk mechanisms involving the IGF-BP-2 system [39].

Mechanistic Pathways and Fibrosis

  • A myofibroblast–mast cell–neuropeptide axis of fibrosis exists in the joint capsules in post-traumatic contractures [11].
  • Epigenetic regulators are critical for normal skeletogenesis and are viable candidate drug targets for short-term local pharmacological strategies to mitigate musculoskeletal tissue degeneration [26].

What the Evidence Shows

Current Clinical Status and Recommendations

  • Orthopaedic and sports medicine providers must understand the current lack of evidence to support the clinical use of peptide therapies, despite their potential therapeutic and regenerative capabilities [1].
  • Due to a lack of robust efficacy and safety data, peptide supplements should not currently be recommended as a replacement or adjunct for existing orthopaedic standard of care [4].
  • The use of BPC-157 for sports performance and recovery is not recommended because there are no randomized controlled trials investigating its use in human subjects, and the science is lacking to determine overall effectiveness, safety profile, and clinical indications [50].
  • Social media posts regarding peptides in musculoskeletal health mostly extrapolate from preclinical or anecdotal data, marketing them as panaceas for health, performance, and aesthetics [32].

Bone Healing and Fracture Repair

  • Osteogenic growth peptide treatment resulted in a stronger expression of transforming growth factor-β both locally and systemically in rat fracture healing models [13].
  • Topical application of nerve growth factor increased the effectiveness and rate of repair of bone in rat fracture models [18].
  • Recombinant human fibroblast growth factor-2 (rhFGF-2) dose-dependently increased the percentage of patients with radiographic bone union and decreased the average time needed for union in a prospective trial on patients with osteotomy [33].
  • Treatment with a scaffold alone improved defect stability at 16 weeks compared to nontreatment but did not achieve bone union or restoration of mechanical function in critically sized bone defects [47].
  • The addition of a BMP binding peptide (BBP) to recombinant human BMP-7 may result in lesser amounts of rhBMP-7 needed to achieve union in the clinical setting [49].
  • Only BMP-2 and BMP-7 can be recommended based on level I studies for carrier systems and application of growth factors in orthopaedics [10].
  • A synthetic growth factor mimetic at a dose of 100 ng per 0.2 mL of injectable demineralized bone matrix (DBM) gel generated the most optimal results for augmenting DBM mineralization [51].
  • Vascular endothelial growth factor (VEGF) is not recommended for enhancement of bone formation during distraction osteogenesis [22].

Tendon and Ligament Healing

  • Platelet-derived growth factor (PDGF) has promise for healing ligaments but must be administered in appropriate doses soon after injury [7].
  • Intralesional insulin-like growth factor-I (IGF-I) has potential use for the treatment of debilitating tendon injuries [9].
  • Recombinant human platelet-derived growth factor-BB (rhPDGF-BB) treatment is an effective therapy and may be an option for clinical applications to treat tendinopathy [16].
  • Injections of rhPDGF-BB at 3 and 10 mg increased maximum load-to-failure, and 10 mg increased stiffness, relative to controls and commonly used treatments in a rat Achilles tendon collagenase model [28].
  • The pentapeptide KTTKS has potential clinical use to improve the process of tendon healing [23].
  • Growth hormone-releasing peptide 2 (GHRP-2) may enhance bone-tendon healing and reduce retear rate after rotator cuff repair [48].

Cartilage and Osteoarthritis

  • Additional in vivo studies are needed to evaluate the potential of growth factors as stimulators in cartilage repair [14].
  • Transduction with interleukin-1 receptor antagonist (IL-1Ra) decreased the synovial expression of IL-1α, IL-1β, and matrix metalloproteinases, indicating a mechanism for prevention of matrix degradation [25].
  • Recombinant fibroblast growth factor-18 (sprifermin) at 100 μg provided the highest treatment benefit for microfracture-induced cartilage healing [27].
  • Treatment with the self-assembling KLD peptide in combination with microfracture resulted in no additional improvements over microfracture-only treatment in an equine model [45].
  • Transforming growth factor-β1 stimulated the expression of the type-II collagen gene in periosteum-derived cells as early as 12 hours after administration, an effect not observed with bone morphogenetic proteins 3 or 4 [20].
  • Patients with advanced osteoarthritis demonstrated little elevation in myeloperoxidase (MPO) levels, and chlorinated peptides were undetectable [44].
  • Suppression of nerve growth factor (NGF) may result in varied effects depending on different stages of the osteoarthritic disease process [58].

Nerve Healing

  • The combination of nerve growth factor and ciliary neurotrophic factor may enhance regeneration in the peripheral nervous system [59].

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

  • GLP-1 receptor agonists may not produce sufficient weight loss to achieve body mass index cutoffs for total joint arthroplasty depending on individual patient factors, including starting bodyweight [30].
  • After adjusting for metabolic confounds, the postulated skeletal benefit of GLP-1 receptor agonists did not translate to meaningful risk reductions for upper extremity fragility fracture [46].

General Regenerative Medicine Context

  • Regenerative medicine holds promise for orthopaedic surgery by developing novel therapies that replace, repair, or promote tissue regeneration [19].
  • The concept of "medicinal signaling cells" has implications for orthopaedic surgeons when counseling patients, selecting biologic adjuncts, interpreting outcome data, and designing future clinical trials [21].

Practical Considerations

Current Status and Recommendations

  • Orthopaedic and sports medicine providers must understand the current lack of evidence to support the clinical use of peptide therapies [1].
  • Due to the lack of robust efficacy and safety data, peptide supplements should not currently be recommended as a replacement or adjunct for existing orthopaedic standard of care [4].
  • Today only BMP-2 and BMP-7 can be recommended based on level I studies [10].

Tendon and Ligament Applications

  • rhPDGF-BB treatment is an effective therapy and may be an option for clinical applications to treat tendinopathy [16].
  • Injections of rhPDGF-BB increased maximum load-to-failure (3 and 10 mg) and stiffness (10 mg) relative to controls and commonly used treatments [28].
  • Findings indicate a benefit to the use of MSCs and AdIGF-MSCs for the treatment of tendinitis [54].

Cartilage and Joint Applications

  • The highest treatment benefit for microfracture-induced cartilage healing was detected following 100 μg sprifermin treatment [27].
  • Therapeutic strategies for microfracture augmentation, such as growth factor–functionalized self-assembling peptide hydrogel scaffolds, can be cost-effective ways to improve cartilage healing outcomes [53].
  • A myofibroblast–mast cell–neuropeptide axis of fibrosis in joint capsules is identified as a potential target for prophylactic or therapeutic interventions in post-traumatic contractures [11].

Bone Healing and Fracture Management

  • Nerve growth factor administration suggests it may play an important role in the healing processes of fractured bone [18].
  • rhFGF-2 dose dependently increased the percentage of patients with radiographic bone union and decreased the average time needed for such union [33].

Perioperative and Systemic Considerations

  • GLP-1 receptor agonists have perioperative implications in total joint arthroplasty patients [29].
  • GLP-1 agonists may not produce sufficient weight loss to achieve body mass index cutoffs for total joint arthroplasty depending on individual patient factors, including starting bodyweight [30].
  • It is no longer acceptable to treat various athletic conditions with medications without accounting for the effects on performance, the medical-legal implications, and the identification of exercise-induced conditions [34].

Safety and Mechanistic Insights

  • Growth factor treatment of chondrocyte cell cultures for cell therapy purposes can be regarded as safe in terms of telomere biology [55].
  • Most social media posts extrapolate from preclinical or anecdotal data, marketing peptides as panaceas for health, performance, and aesthetics [32].

Key Evidence

  • [L5] While peptide therapy may possess significant therapeutic and regenerative potential, it is critical that orthopaedic and sports medicine providers understand the current lack of evidence to support the clinical use of these peptides. [1] (10.1177/03635465251357593)
  • [Paper] We anticipate that such peptides may be coupled to therapeutic molecules to provide targeted treatment for cartilage disorders. [2] (10.1002/jor.22325)
  • [Paper] Peptide therapeutics in orthopaedics have evolved from naturally occurring agents like bone morphogenetic proteins to rationally engineered synthetics. [3] (10.2106/jbjs.26.00785)
  • [L5] Because of the lack of robust efficacy and safety data, peptide supplements should not currently be recommended as a replacement or adjunct for existing orthopaedic standard of care. [4] (10.1177/03635465261464420)
  • [Paper] It has become clear that growth factors play a critical role in the biologic processes that drive tendons to heal. [5] (10.1197/j.jht.2005.01.012)
  • [Paper] These results indicate that platelet-derived growth factor has promise for healing ligaments but that it must be administered in appropriate doses soon after injury. [7] (10.1002/jor.1100140509)
  • [L5] Injectable peptides for sports medicine remain largely experimental. [8] (10.2106/jbjs.rvw.26.00027)
  • [Paper] These data support the potential use of intralesional IGF-I for treatment of debilitating tendon injuries. [9] (10.1016/s0736-0266(02)00009-8)
  • [Paper] Today only BMP-2 and BMP-7 can be recommended based on level I studies. [10] (10.1016/s0020-1383(08)70014-7)
  • [L5] These observations identify putative mechanistic components of a myofibroblast–mast cell–neuropeptide axis of fibrosis in the joint capsules in post-traumatic contractures and potential prophylactic or therapeutic interventions. [11] (10.1002/jor.22676)
  • [L4] Our results suggest that parathyroid hormone-related peptide may be involved in the pathophysiology of osteoarthritis. [12] (10.1002/jor.1100150204)
  • [Paper] The specimens treated with osteogenic growth peptide had a stronger expression of transforming growth factor-β, both locally and systemically. [13] (10.1002/jor.1100180119)
  • [Paper] Additional in vivo studies are needed to evaluate the potential of these growth factors as stimulators in cartilage repair. [14] (10.1002/jor.1100180111)
  • [Paper] Local delivery of specific neuropeptides could reverse the functional deficits of these neuropathic ligaments in only 2 weeks. [15] (10.1002/jor.20335)
  • [Paper] Data suggest that rhPDGF-BB treatment is an effective therapy and may be an option for clinical applications to treat tendinopathy. [16] (10.1002/jor.22222)
  • [Paper] Although growth factors have the potential to modulate soft-tissue repair, tissue responses in tendons and ligaments may vary at different anatomic sites. [17] (10.1002/jor.1100140407)
  • [Paper] The resultant increases in effectiveness and rate of repair of bone with administration of nerve growth factor suggest that it may play an important role in the healing processes of fractured bone. [18] (10.1002/jor.1100150212)
  • [L5] Regenerative medicine holds great promise for orthopaedic surgery by developing novel therapies that replace, repair, or promote tissue regeneration. [19] (10.1002/jor.20432)
  • [Paper] This effect was observed as early as 12 hours after administration of transforming growth factor-β1 but was not observed in response to bone morphogenetic proteins 3 or 4. [20] (10.1002/jor.1100150321)
  • [L5] Caplan’s term “medicinal signaling cells” and has important implications for orthopaedic surgeons when counseling patients, selecting biologic adjuncts, interpreting outcome data, and designing future clinical trials. [21] (10.5435/jaaos-d-26-00882)
  • [Paper] VEGF is not recommended for enhancement of bone formation in this setting. [22] (10.1016/s0736-0266(02)00159-6)
  • [Paper] These findings strongly implicated the potential clinical use of pentapeptide KTTKS to improve the process of tendon healing in the future. [23] (10.1002/jor.20455)
  • [L3] These data indicate that effective mechanisms of growth factor delivery for articular cartilage repair may differ for different growth factors. [24] (10.1002/jor.22444)
  • [Paper] Transduction with IL-1Ra decreased the synovial expression of IL-1α and IL-1β and matrix metalloproteinases, indicating a mechanism for prevention of matrix degradation. [25] (10.1016/j.orthres.2004.06.020)
  • [Paper] The combined body of molecular and genetic studies focusing on epigenetic regulators indicates that these proteins are critical for normal skeletogenesis and viable candidate drug targets for short-term local pharmacological strategies to mitigate musculoskeletal tissue degeneration. [26] (10.1002/jor.24305)
  • [Paper] We detected the highest treatment benefit following 100 μg sprifermin treatment. [27] (10.1002/jor.25063)
  • [L3] Injections of rhPDGF-BB increased maximum load-to-failure (3 and 10 m g) and stiffness (10 m g) relative to controls and commonly used treatments. [28] (10.1002/jor.22483)
  • [Paper] This review critically appraises current evidence on perioperative implications of GLP-1 receptor agonists in total joint arthroplasty patients. [29] (10.5435/jaaos-d-25-00892)
  • [Paper] While efficacious, GLP-1 agonists may not produce sufficient weight loss to achieve body mass index cutoffs for total joint arthroplasty depending on individual patient factors, including starting bodyweight. [30] (10.2106/jbjs.rvw.23.00167)
  • [Paper] In the first 2 weeks after lesion induction, tissue levels of IGF-I protein actually decreased approximately 40% compared to normal tendon. [31] (10.1016/j.orthres.2004.05.007)
  • [Paper] Most posts extrapolate from preclinical or anecdotal data, marketing peptides as panaceas for health, performance, and aesthetics, as evidenced by the poor DISCERN scores. [32] (10.1177/2325967126s00290)
  • [L2] The rhFGF-2 dose dependently increased the percentage of patients with radiographic bone union, and decreased the average time needed for such union. [33] (10.1002/jor.20315)
  • [Paper] It is no longer acceptable to treat various athletic conditions with medications without accounting for the effects on performance, the medical-legal implications, and the identification of exercise-induced conditions. [34] (10.1016/s0278-5919(05)70076-4)
  • [Paper] In conclusion, local growth factor application enhances the healing in the early phase without alteration of the normal healing process. [35] (10.1016/j.orthres.2003.09.009)
  • [L5] The findings support the hypothesis that cartilage fragments from osteoarthritic knee promote chondrogenic differentiation without exogenous growth factor induction. [37] (10.1002/jor.21541)
  • [Paper] This suggests the hypothesis that the actions of these IGFBPs in articular cartilage extend beyond the classic modulation of IGF receptor action. [38] (10.1002/jor.20660)
  • [Paper] These data help to support the postulate that TGF-β exerts at least some of its actions in articular cartilage via cross-talk mechanisms involving the IGF-BP-2 system. [39] (10.1016/s0736-0266(02)00154-7)
  • [Paper] These findings indicate that interventions developed to improve healing of these tissues will have to address these differences, because they will likely affect the outcomes. [40] (10.1016/j.jhsa.2006.06.011)
  • [Paper] SDF-1b provides potent synergistic effects supporting BMSC-mediated bone formation and appears a suitable candidate for optimization of bone augmentation in translational protocols. [41] (10.1002/jor.22749)
  • [Paper] The results of this study document the IGFBP response of flexor tendons to injury and healing, which provides information necessary for the design of protocols that may enhance tendon healing through manipulation of IGF-I ligand and binding protein levels. [42] (10.1002/jor.20000)
  • [L4] Patients in the control and advanced OA groups demonstrated little elevation in MPO levels and Cl-peptides were undetectable. [44] (10.1002/jor.20400)
  • [L5] Treatment with the self-assembling KLD peptide in combination with microfracture resulted in no additional improvements over microfracture-only treatment. [45] (10.2106/jbjs.m.01408)
  • [L3] After adjusting for metabolic confounds, we found that the postulated skeletal benefit of GLP 1RAs did not translate to meaningful risk reductions in this population. [46] (10.1016/j.injury.2026.113456)
  • [Paper] Treatment with scaffold alone improved defect stability at 16 weeks compared to nontreatment, but did not achieve bone union or restoration of mechanical function. [47] (10.1002/jor.20372)
  • [L5] The present study might be a transitional study to show the efficacy of GHRP-2 in enhancing bone-tendon healing and reduce retear rate after rotator cuff repair. [48] (10.1016/j.arthro.2024.11.094)
  • [Paper] Improved healing imparted by the addition of BBP may result in lesser amounts of rhBMP-7 needed to achieve union in the clinical setting. [49] (10.1002/jor.21252)
  • [L5] The authors do not recommend the use of BPC-157 for sports performance and recovery because there are no randomized controlled trials investigating its use in human subjects, and the science is clearly lacking to determine the overall effectiveness, safety profile, and clinical indications for sports enhancement in athletes. [50] (10.1016/j.arthro.2024.09.005)
  • [Paper] In these studies, 100 ng of peptide per 0.2 mL of injectable DBM gel generated the most optimal results. [51] (10.1002/jor.20215)
  • [L5] Therapeutic strategies for microfracture augmentation, such as those presented in this study, can be cost-effective ways to improve cartilage healing outcomes. [53] (10.1177/03635465211021798)
  • [Paper] These findings indicate a benefit to the use of MSCs and AdIGF-MSCs for the treatment of tendinitis. [54] (10.1002/jor.20887)
  • [Paper] Growth factor treatment of chondrocyte cell cultures for cell therapy purposes can be regarded as safe in terms of telomere biology. [55] (10.1002/jor.21007)
  • [Paper] The use of BMP currently has two FDA-approved indications: treatment of open tibial fractures treated with intramedullary fixation and treatment of tibia long bone non-union. [57] (10.1016/s0020-1383(13)70008-1)
  • [Paper] Suppression of NGF may result in varied effects depending on different stages of the osteoarthritic disease process. [58] (10.1002/jor.25382)
  • [Paper] These data support the conclusion that the use of nerve growth factor and ciliary neurotrophic factor in combination may enhance regeneration in the peripheral nervous system. [59] (10.1053/jhsu.2001.24148)

References

[1] Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American Journal of Sports Medicine. 2026. DOI: 10.1177/03635465251357593

[2] Identification of chondrocyte‐binding peptides by phage display. Journal of Orthopaedic Research. 2013. DOI: 10.1002/jor.22325

[3] Peptide Therapeutics in Orthopaedics. Journal of Bone and Joint Surgery. 2026. DOI: 10.2106/jbjs.26.00785

[4] Peptide Supplements and Their Therapeutic Applications in Sports Medicine. The American Journal of Sports Medicine. 2026. DOI: 10.1177/03635465261464420

[5] The Use of Growth Factors on Tendon Injuries. Journal of Hand Therapy. 2005. DOI: 10.1197/j.jht.2005.01.012

[7] Influence of dosage and timing of application of platelet‐derived growth factor on early healing of the rat medial collateral ligament. Journal of Orthopaedic Research. 1996. DOI: 10.1002/jor.1100140509

[8] Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS Reviews. 2026. DOI: 10.2106/jbjs.rvw.26.00027

[9] Insulin‐like growth factor‐I improves cellular and molecular aspects of healing in a collagenase‐induced model of flexor tendinitis. Journal of Orthopaedic Research. 2002. DOI: 10.1016/s0736-0266(02)00009-8

[10] Carrier systems and application of growth factors in orthopaedics. Injury. 2008. DOI: 10.1016/s0020-1383(08)70014-7

[11] A myofibroblast-mast cell-neuropeptide axis of fibrosis in post-traumatic joint contractures: An in vitro analysis of mechanistic components. Journal of Orthopaedic Research. 2014. DOI: 10.1002/jor.22676

[12] Expression of parathyroid hormone‐related peptide in human osteoarthritis. Journal of Orthopaedic Research. 1997. DOI: 10.1002/jor.1100150204

[13] Osteogenic growth peptide normally stimulated by blood loss and marrow ablation has local and systemic effects on fracture healing in rats. Journal of Orthopaedic Research. 2000. DOI: 10.1002/jor.1100180119

[14] Responsiveness of bovine chondrocytes to growth factors in medium with different serum concentrations. Journal of Orthopaedic Research. 2000. DOI: 10.1002/jor.1100180111

[15] Adjuvant neuropeptides can improve neuropathic ligament healing in a rat model. Journal of Orthopaedic Research. 2007. DOI: 10.1002/jor.20335

[16] Dose–response effect of an intra‐tendon application of recombinant human platelet‐derived growth factor‐BB (rhPDGF‐BB) in a rat Achilles tendinopathy model. Journal of Orthopaedic Research. 2012. DOI: 10.1002/jor.22222

[17] Patellar tendon and anterior cruciate ligament have different mitogenic responses to platelet‐derived growth factor and transforming growth factor β. Journal of Orthopaedic Research. 1996. DOI: 10.1002/jor.1100140407

[18] Topical application of nerve growth factor improves fracture healing in rats. Journal of Orthopaedic Research. 1997. DOI: 10.1002/jor.1100150212

[19] Regenerative medicine in orthopaedic surgery. Journal of Orthopaedic Research. 2007. DOI: 10.1002/jor.20432

[20] Regulation of the expression of the type‐II collagen gene in periosteum‐derived cells by three members of the transforming growth factor–β superfamily. Journal of Orthopaedic Research. 1997. DOI: 10.1002/jor.1100150321

[21] Clinical Translation of Mesenchymal Stem Cells to Medicinal Signaling Cells: Origins, Clinical Applications, and the Future of Regenerative Medicine–2026 Arnold I. Caplan Award for Distinguished Research in Orthobiologics. Journal of the American Academy of Orthopaedic Surgeons. 2026. DOI: 10.5435/jaaos-d-26-00882

[22] Effects of locally applied vascular endothelial growth factor (VEGF) and VEGF‐inhibitor to the rabbit tibia during distraction osteogenesis. Journal of Orthopaedic Research. 2003. DOI: 10.1016/s0736-0266(02)00159-6

[23] The pentapeptide KTTKS promoting the expressions of type I collagen and transforming growth factor‐β of tendon cells. Journal of Orthopaedic Research. 2007. DOI: 10.1002/jor.20455

[24] Endogenous versus exogenous growth factor regulation of articular chondrocytes. Journal of Orthopaedic Research. 2013. DOI: 10.1002/jor.22444

[25] Dual transduction of insulin‐like growth factor‐I and interleukin‐l receptor antagonist protein controls cartilage degradation in an osteoarthritic culture model. Journal of Orthopaedic Research. 2005. DOI: 10.1016/j.orthres.2004.06.020

[26] Epigenetics as a New Frontier in Orthopedic Regenerative Medicine and Oncology. Journal of Orthopaedic Research. 2019. DOI: 10.1002/jor.24305

[27] Recombinant fibroblast growth factor‐18 (sprifermin) enhances microfracture‐induced cartilage healing. Journal of Orthopaedic Research. 2021. DOI: 10.1002/jor.25063

[28] Comparison of the effect of intra‐tendon applications of recombinant human platelet‐derived growth factor‐BB, platelet‐rich plasma, steroids in a rat achilles tendon collagenase model. Journal of Orthopaedic Research. 2013. DOI: 10.1002/jor.22483

[29] The Effect of Glucagon-like Peptide-1 Receptor Agonists in Total Joint Arthroplasty: Implications, Complications, and Considerations. Journal of the American Academy of Orthopaedic Surgeons. 2026. DOI: 10.5435/jaaos-d-25-00892

[30] Glucagon-like Peptide-1 Agonists. JBJS Reviews. 2024. DOI: 10.2106/jbjs.rvw.23.00167

[31] Temporal expression of growth factors and matrix molecules in healing tendon lesions. Journal of Orthopaedic Research. 2005. DOI: 10.1016/j.orthres.2004.05.007

[32] Paper 32. Performance & Promises: A Social Media Review of Alleged Indications, Risks and Usage of “Peptides” in Musculoskeletal Health. Orthopaedic Journal of Sports Medicine. 2026. DOI: 10.1177/2325967126s00290

[33] Local application of recombinant human fibroblast growth factor‐2 on bone repair: A dose–escalation prospective trial on patients with osteotomy. Journal of Orthopaedic Research. 2007. DOI: 10.1002/jor.20315

[34] PREFACE. Clinics in Sports Medicine. 1998. DOI: 10.1016/s0278-5919(05)70076-4

[35] Long‐term effects of local growth factor (IGF‐I and TGF‐β1) treatment on fracture healing. A safety study for using growth factors. Journal of Orthopaedic Research. 2004. DOI: 10.1016/j.orthres.2003.09.009

[37] Cartilage fragments from osteoarthritic knee promote chondrogenesis of mesenchymal stem cells without exogenous growth factor induction. Journal of Orthopaedic Research. 2011. DOI: 10.1002/jor.21541

[38] Subcellular distribution of the insulin‐like growth factor (IGF) binding proteins (IGFBPs) 2 and 3 in articular chondrocytes. Journal of Orthopaedic Research. 2008. DOI: 10.1002/jor.20660

[39] Localization of insulin‐like growth factor binding protein‐2 in chondrocytes of bovine articular cartilage. Journal of Orthopaedic Research. 2003. DOI: 10.1016/s0736-0266(02)00154-7

[40] Patterns of mRNA Expression for Matrix Molecules and Growth Factors in Flexor Tendon Injury: Differences in the Regulation Between Tendon and Tendon Sheath. The Journal of Hand Surgery. 2006. DOI: 10.1016/j.jhsa.2006.06.011

[41] Mesenchymal stem cell expression of stromal cell‐derived factor‐1β augments bone formation in a model of local regenerative therapy. Journal of Orthopaedic Research. 2014. DOI: 10.1002/jor.22749

[42] Expression of insulin‐like growth factor binding proteins in healing tendon lesions. Journal of Orthopaedic Research. 2005. DOI: 10.1002/jor.20000

[43] Orthopaedic Basic Science Fifth Edition Print Ebook. Cells and Materials for Soft-Tissue Repair and Regeneration > Introduction.

[44] Myeloperoxidase and chlorinated peptides in osteoarthritis: potential biomarkers of the disease. Journal of Orthopaedic Research. 2007. DOI: 10.1002/jor.20400

[45] Effects of the Combination of Microfracture and Self-Assembling Peptide Filling on the Repair of a Clinically Relevant Trochlear Defect in an Equine Model. Journal of Bone and Joint Surgery. 2014. DOI: 10.2106/jbjs.m.01408

[46] Glucagon-like peptide-1 receptor agonist use for type 2 diabetes and risk of upper extremity fragility fracture. Injury. 2026. DOI: 10.1016/j.injury.2026.113456

[47] Quantitative assessment of scaffold and growth factor‐mediated repair of critically sized bone defects. Journal of Orthopaedic Research. 2007. DOI: 10.1002/jor.20372

[48] Growth Hormone–Releasing Peptide 2 May Be Associated With Decreased M1 Macrophage Production and Increased Histologic and Biomechanical Tendon‐Bone Healing Properties in a Rat Rotator Cuff Tear Model. Arthroscopy. 2024. DOI: 10.1016/j.arthro.2024.11.094

[49] Enhancement of recombinant human BMP‐7 bone formation with bmp binding peptide in a rodent femoral defect model. Journal of Orthopaedic Research. 2010. DOI: 10.1002/jor.21252

[50] Injectable Therapeutic Peptides—An Adjunct to Regenerative Medicine and Sports Performance?. Arthroscopy. 2024. DOI: 10.1016/j.arthro.2024.09.005

[51] Augmentation of demineralized bone matrix (DBM) mineralization by a synthetic growth factor mimetic. Journal of Orthopaedic Research. 2006. DOI: 10.1002/jor.20215

[53] Microfracture Augmentation With Trypsin Pretreatment and Growth Factor–Functionalized Self-assembling Peptide Hydrogel Scaffold in an Equine Model. The American Journal of Sports Medicine. 2021. DOI: 10.1177/03635465211021798

[54] Mesenchymal stem cells and insulin‐like growth factor‐I gene‐enhanced mesenchymal stem cells improve structural aspects of healing in equine flexor digitorum superficialis tendons. Journal of Orthopaedic Research. 2009. DOI: 10.1002/jor.20887

[55] Influence of the growth factors PDGF‐BB, TGF‐β1 and bFGF on the replicative aging of human articular chondrocytes during in vitro expansion. Journal of Orthopaedic Research. 2009. DOI: 10.1002/jor.21007

[57] Clinical applications of growth factors in bone injuries: Experience with BMPs. Injury. 2013. DOI: 10.1016/s0020-1383(13)70008-1

[58] Nerve growth factor receptors in equine synovial membranes vary with osteoarthritic disease severity. Journal of Orthopaedic Research. 2022. DOI: 10.1002/jor.25382

[59] Axonal regeneration stimulated by the combination of nerve growth factor and ciliary neurotrophic factor in an end-to-side model. The Journal of Hand Surgery. 2001. DOI: 10.1053/jhsu.2001.24148